The disruptors at EQRx have their eyes on the PD-(L)1 market — teeing up $150M cash to grab 2 backbone therapies from China
EQRx is paying top dollar to bring a pair of PD-(L)1 drugs into its portfolio of fast-follow therapies, offering $150 million upfront in what could …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
